{"text": "Of the 312 participants meeting inclusion criteria (138 [44.2%] were female; mean [SD] age, 67.8 [12.1] years), 25 (8.0%) had IOP elevation more than 10 mm Hg over baseline through month 60, and 5 (1.6%) had IOP higher than 35 mm Hg.\nThe 60-month Kaplan-Meier cumulative incidence of IOP elevation more than 10 mm Hg over baseline was 0.13 (95% CI, 0.08-0.19), and the 60-month Kaplan-Meier cumulative incidence of IOP higher than 35 mm Hg was 0.02 (95% CI, 0.01-0.06), and did not differ among participants initially randomly assigned to receive aflibercept or bevacizumab.\nThree participants (1.0%) underwent IOP-lowering incisional surgery, and 3 participants (1.0%) underwent IOP-lowering glaucoma laser surgery.", "label": []}
{"text": "A total of 98 eyes were enrolled, including 50 in the EX-PRESS group and 48 in the NPDS group.\nAt 12\u00a0months, IOP (mean\u00a0\u00b1\u00a0SD) was 13.9\u00a0\u00b1\u00a03.3\u00a0mmHg in EX-PRESS group and 13.3\u00a0\u00b1\u00a03.6\u00a0mmHg in NPDS group (p\u00a0=\u00a00.38).\nSuccess rate was 75% and 80% in EX-PRESS and NPDS groups, respectively (p\u00a0=\u00a00.53).\nThe number of glaucoma medications (mean\u00a0\u00b1\u00a0SD) was 0.2\u00a0\u00b1\u00a00.55 in EX-PRESS group and 0.17\u00a0\u00b1\u00a00.44 in NPDS group (p\u00a0=\u00a01.00).\nThe total number of complications was 66 in 35 subjects in EX-PRESS group and 39 in 23 subjects in NPDS group (p\u00a0=\u00a00.02).\nThe incidence of more than one complication was n\u00a0=\u00a013 (26%) versus n\u00a0=\u00a09 (18.8%) in EX-PRESS and NPDS groups, respectively (p\u00a0=\u00a00.38).\nThe total number of required postoperative interventions was 59 and 26 in EX-PRESS and NPDS groups, respectively (p\u00a0=\u00a00.01).\nVisual acuity was similar in both groups at month 12 (p\u00a0=\u00a00.13).\nSurgical time (mean\u00a0\u00b1\u00a0SD) was 52.6\u00a0\u00b1\u00a013.6\u00a0min in EX-PRESS group and 63.3\u00a0\u00b1\u00a019.4\u00a0min in NPDS group (p\u00a0=\u00a00.01).", "label": []}
{"text": "Among 362 randomized participants (mean [SD] age, 69 [12] years; 157 [43.4%] women; mean [SD] VALS at baseline, 50.3 [15.2] [approximate Snellen VA 20/100]), 348 (96.1%) completed the month 6 follow-up visit.\nAt month 6, the mean VALS was 69.3 (a mean increase from baseline of 18.6) in the bevacizumab group and 69.3 (a mean increase from baseline of 18.9) in the aflibercept group (model-based estimate of between-group difference, -0.14; 97.5% CI, -3.07 to \u221e; P\u2009=\u2009.001 for noninferiority), meeting criteria for noninferiority.\nOcular adverse events in the aflibercept group included 4 participants with intraocular pressure (IOP) more than 10 mm Hg greater than baseline; ocular adverse events in the bevacizumab group included 1 participant with endophthalmitis (culture negative), 9 with IOP more than 10 mm Hg greater than baseline, 2 with IOP higher than 35 mm Hg, and 1 with angle-closure glaucoma not attributed to the study drug or procedure.", "label": []}
{"text": "No significant differences in composite scores were observed between treatment groups, and no significant change in scores were seen over time.\nMean (SD; range) values of clinical anchors at baseline were\u00a0-16.6 (9.3;\u00a0-32 to\u00a0-0.5) dB for the surgical eye and 0.2 (0.3;\u00a0-0.1 to 1.3) logMAR VA in the better-vision eye.\nFor anchor-based cross-sectional analysis, composite score MID (95% CI) was 6.3 (4.6-7.9) for better-eye VA and 1.4 (0.9-1.9) for surgical eye MD.\nDistribution-based MID for the composite score was 6.0.", "label": []}
{"text": "Mean \u00b1 SD patient age was 60 \u00b1 10 years; most patients were male and white.\nCompared with TRAV+TIM (n\u00a0= 40), patients receiving TTFC (n\u00a0= 41) were consistently adherent on a greater percentage of days through month 12 (60% vs 43%).\nAt months 1, 3, 6, and 12, 80% adherence was achieved by 71% vs 38%, 53% vs 30%, 45% vs 16%, and 32% vs 11% of patients receiving TTFC vs TRAV+TIM, respectively.\nSignificantly more patients were adherent on \u226580% of days with TTFC compared with TRAV+TIM (P\u00a0<\u00a0.001 to P\u00a0= .041).\nBoth treatments reduced IOP from baseline, and no safety issues were identified in either group.\nOcular hyperemia was the most common treatment-related adverse event (n\u00a0= 3/group).", "label": []}
{"text": "Thirty adults were randomized into 2 groups.\nThe mean (\u00b1SD) pretreatment IOP was 20.21\u00b13.19 mm Hg for the study group (n=14) and 21.14\u00b12.98 mm Hg for the controls (n=14; P =0.43), dropping to 15.50\u00b13.77 and 15.00\u00b14.08 mm Hg (P =0.74) after 6 months and to 16.00\u00b13.31 and 14.00\u00b12.45 mm Hg (P =0.22) after 12 months.\nThe average IOP reduction after 6 and 12 months was 23.4% and 20.83% for the study group and 27.1% and 33.77% for the controls (P=0.528).\nSuccess (a decrease of \u226515% at 6 months with no additional medications, laser, or glaucoma surgery) was achieved in 12 (85.7%) study patients and 9 (69.2%) controls (P=0.385).\nComplications were mild and transient (n=30), although significantly higher in the controls (n=15; P <0.0001).", "label": []}
{"text": "In Study 1, the adjusted mean IOP reductions (95% confidence interval [CI]) were 2.9 (2.5-3.3) mm Hg and 1.6 (1.2-2.0) mm Hg in the OPC-1085EL and latanoprost groups, respectively (P < .0001).\nIn Study 2, the adjusted mean IOP reductions (95% CI) were 3.5 (3.1-3.9) mm Hg and 1.6 (1.2-2.0) mm Hg in the OPC-1085EL and carteolol groups, respectively (P < .0001).\nAll adverse drug reactions of OPC-1085EL observed in both studies were mild in severity and only 1 patient in each study discontinued because of an adverse drug reaction.", "label": []}
{"text": "Among 222 eligible patients, 13 (5.9%) refused and 209 (94.1%) were enrolled, with 106 (50.7%) randomized to the intervention group (mean [SD] age, 64.4 [12.7] years; 56 women [52.8%]) and 103 (49.3%) to the control group (mean [SD] age, 63.0 [12.7] years; 53 women [51.5%]).\nA total of 6 patients (2.9%) were unavailable for follow-up.\nAttendance at 1 month for the intervention group (59 of 102\u2009[57.8%]) was significantly higher than for the control group (34 of 101\u2009[33.7%]) (unadjusted relative risk [RR],\u20091.72; 95% CI, 1.13-2.63; P\u2009=\u2009.01).\nFactors associated with 1-month attendance in multiple regression models included intervention group membership (RR,\u20091.65; 95% CI, 1.08-2.53; P\u2009=\u2009.02) and being told to return for suture removal (RR,\u20091.80; 95% CI, 1.06-3.06; P\u2009=\u2009.03).\nOne-month attendance among controls not told about suture removal was 3 of 31\u2009(9.7%), whereas it was 44 of 68\u2009(64.7%) among the intervention group with suture removal (unadjusted RR,\u20096.69; 95% CI, 2.08-21.6; P\u2009=\u2009.001).", "label": []}
{"text": "Mean diurnal IOP at week 6 (least squares mean \u00b1 standard error) was 17.6 \u00b1 0.4\u00a0mm Hg and 20.7 \u00b1 0.4\u00a0mm Hg in the BBFC+TRAV and vehicle+TRAV groups, respectively (between-group difference,\u00a0-3.2 \u00b1 0.5\u00a0mm Hg; P < .0001).\nSuperiority of BBFC+TRAV over vehicle+TRAV was established.\nMean and percent diurnal IOP change from baseline were significantly greater with BBFC+TRAV compared with vehicle+TRAV (P < .0001 for both).\nConjunctival hyperemia was the most common treatment-related adverse event in either group (BBFC+TRAV, 12.8%; vehicle+TRAV, 6.0%).", "label": []}
{"text": "Late complications developed in 56 subjects (46.8 \u00b1 4.8 5-year cumulative % \u00b1 SE) in the Ahmed Glaucoma Valve group and 67 (56.3 \u00b1 4.7 5-year cumulative % \u00b1 SE) in the Baerveldt Glaucoma Implant group (P = .082).\nThe cumulative rates of serious complications were 15.9% and 24.7% in the Ahmed Glaucoma Valve and Baerveldt Glaucoma Implant groups, respectively (P = .034), although this was largely driven by subjects who had tube occlusions in the 2 groups (0.8% in the Ahmed Glaucoma Valve group and 5.7% in the Baerveldt Glaucoma Implant group, P = .037).\nBoth groups had a relatively high incidence of persistent diplopia (12%) and corneal edema (20%), although half of the corneal edema cases were likely due to pre-existing causes other than the aqueous shunt.\nThe incidence of tube erosion was 1% and 3% in the Ahmed Glaucoma Valve and Baerveldt Glaucoma Implant groups, respectively (P = .04).", "label": []}
{"text": "Product limit estimates of the risk for glaucoma and glaucoma\u2009+\u2009glaucoma suspect at 4.8 years after surgery were 17% (95% CI, 11%-25%) and 31% (95% CI, 24%-41%), respectively.\nThe contact lens and IOL groups were not significantly different for either outcome: glaucoma (hazard ratio [HR], 0.8; 95% CI, 0.3-2.0; P\u2009=\u2009.62) and glaucoma\u2009+\u2009glaucoma suspect (HR, 1.3; 95% CI, 0.6-2.5; P\u2009=\u2009.58).\nYounger (vs older) age at surgery conferred an increased risk for glaucoma (26% vs 9%, respectively) at 4.8 years after surgery (HR, 3.2; 95% CI, 1.2-8.3), and smaller (vs larger) corneal diameter showed an increased risk for glaucoma\u2009+\u2009glaucoma suspect (HR, 2.5; 95% CI, 1.3-5.0).\nAge and corneal diameter were significantly positively correlated.\nGlaucoma was predominantly open angle (19 of 20 cases, 95%), most eyes received medication (19 of 20, 95%), and 8 of 20 eyes (40%) underwent surgery.", "label": []}
{"text": "Twenty-two patients volunteered and 11 (50.0%) completed the study; 8 (36.4%) did not complete treatment owing to changes of health, moving away, lack of transportation, or family crisis; and 3(13.6%) were withdrawn owing to needle sensitivity or IOP elevation (8 mm Hg) in the contralateral eye.\nAfter an acupuncture session, mean IOP increased slightly with both eye-points (from 12.9 \u00b1 1.8 mm Hg to 13.6 \u00b1 2.0 mm Hg, P = .019) and non-eye-points (from 13.0 \u00b1 1.5 mm Hg to 13.5 \u00b1 1.7 mm Hg, P = .073) series.\nHR, diurnal IOP, and BCVA showed no statistically significant changes after 12 sessions of either series.\nSystolic and diastolic BP were reduced after 12 sessions of non-eye-points series (P = .040, P = .002, respectively).\nOptic disc, RNFL, and VF showed no statistically significant changes.", "label": []}
{"text": "Mean IOP was similar between groups at all study visits (travoprost 0.003% range, 17.5-18.9 mm Hg; travoprost 0.004% range, 17.4-19.0 mm Hg).\nMean change (least squares mean differences, -0.1 to 0.3 mm Hg; 95% confidence interval, -0.5 to 0.7 mm Hg) and percentage change (travoprost 0.003%, 28.4%-30.7%; travoprost 0.004%, 28.5%-31.0%) from baseline were comparable.\nThe percentages of patients with IOP <18 mm Hg and \u226530% reduction of IOP were also similar.\nHyperemia was the most frequent treatment-related adverse event with both formulations (travoprost 0.003%, 11.8%; travoprost 0.004%, 14.5%).", "label": []}
{"text": "In the ripasudil-timolol study, the mean IOP reductions from baseline in the ripasudil and placebo groups were -2.4 and -1.5 mm Hg at 9 am for a difference of 0.9 mm Hg (95% CI, 0.4-1.3 mm Hg; P\u2009<\u2009.001) and -2.9 and -1.3 mm Hg at 11 am for a difference of 1.6 mm Hg (95% CI, 1.1-2.1 mm Hg; P\u2009<\u2009.001), respectively.\nIn the ripasudil-latanoprost study, those IOP reductions were -2.2 and -1.8 mm Hg at 9 am for a difference of 0.4 mm Hg (95% CI, -0.0 to 0.9 mm Hg; P\u2009=\u2009.06) and -3.2 and -1.8 mm Hg at 11 am for a difference of 1.4 mm Hg (95% CI, 0.9-1.9 mm Hg; P\u2009<\u2009.001), respectively.\nThe most frequently reported adverse event was conjunctival hyperemia, which was mild and in most cases resolved without treatment before the next instillation.", "label": []}
{"text": "Fifty patients (96 eyes) were randomized to SLT and 50 patients (99 eyes) to PGA medical therapy.\nAt 6 months, 49 patients in the SLT group and 47 in the PGA group completed follow-up.\nAnalysis was based on intent to treat.\nAt 6 months, IOP decreased by 4.0 mm Hg (95% CI, 3.2-4.8) in the SLT group (P\u2009<\u2009.001) and by 4.2 mm Hg (95% CI, 3.5-4.9) in the PGA group (P\u2009<\u2009.001).\nThere were no differences between the SLT and PGA groups in the absolute mean reduction of IOP (4.0 vs 4.2 mm Hg, respectively; P\u2009=\u2009.78) or in the percentage of reduction in IOP (16.9% vs 18.5%, respectively; P\u2009=\u2009.52).\nComplete success (IOP \u226421 mm Hg without medications) was achieved in 60.0% eyes of the SLT group, compared with 84.0% of eyes in the PGA group (P\u2009=\u2009.008).\nNo patients required glaucoma surgery.\nAdditional medications were required in 22.0% of patients in the SLT group compared with 8.0% in the PGA group (P\u2009=\u2009.05).\nOne patient in the SLT group (2.0%) had a transient posttreatment IOP spike greater than 5 mm Hg.\nThe mean endothelial cell count showed a significant decrease from baseline in the SLT arm (4.8% decrease; P\u2009=\u2009.001).\nNo other events such as persistent uveitis or increase in peripheral anterior synechiae were noted in eyes that underwent SLT.\nTwo patients in the PGA group exited owing to drug-related complications (1 patient with uveitis and 1 with allergic conjunctivitis).", "label": []}
{"text": "The 10-year cumulative probability of graft failure was higher in participants with PACE than in those with Fuchs dystrophy (37% vs 20%; hazard ratio [HR], 2.1 [99% CI, 1.4-3.0]; P\u2009<\u2009.001) and in participants with a history of glaucoma before penetrating keratoplasty, particularly with prior glaucoma surgery (58% with prior glaucoma surgery and use of medications to lower intraocular pressure at the time of surgery vs 22% with no history of glaucoma surgery or medication use; HR, 4.1 [99% CI, 2.2-7.5]; P\u2009<\u2009.001).\nWe found trends toward increased graft failure in recipients who were 70 years or older compared with those younger than 60 years (29% vs 19%; HR, 1.2 [99% CI, 0.7-2.1]; P\u2009=\u2009.04) or were African American (HR, 1.5; P\u2009=\u2009.11) or who had a history of smoking (35% vs 24%; HR, 1.6 [99% CI, 0.9-2.8]; P\u2009=\u2009.02).\nLower endothelial cell density (ECD) and higher corneal thickness (CT) at 6 months (6% vs 41% for ECD \u22652700 vs <1700 cells/mm2 [P\u2009<\u2009.001]; 14% vs 36% for CT <500 vs \u2265600 \u03bcm [P\u2009=\u2009.001]), 1 year (4% vs 39% for ECD \u22652700 vs <1700 cells/mm2 [P\u2009<\u2009.001]; 18% vs 28% for CT <500 vs \u2265600 \u03bcm [P\u2009=\u2009.04]), and 5 years (2% vs 29% for ECD \u22651500 vs <500 cells/mm2 [P\u2009<\u2009.001]; 7% vs 34% for CT <550 vs \u2265650 \u03bcm [P\u2009<\u2009.001]) were associated with subsequent graft failure.", "label": []}
{"text": "Baseline diurnal IOP was similar among groups (mean \u00b1 standard deviation: BBFC, 25.9 \u00b1 0.19 mmHg; brinzolamide, 25.9 \u00b1 0.20 mmHg; brimonidine, 26.0 \u00b1 0.19 mmHg).\nAt month 3, BBFC lowered mean diurnal IOP from baseline to a significantly greater extent than brinzolamide (least squares [LS] mean difference: -1.4 mmHg; P < 0.0001; t test) and brimonidine (LS mean difference: -1.5 mmHg; P < 0.0001).\nAll supportive end points corroborated the results of the primary efficacy analysis.\nMean percentage reductions in IOP from baseline were 26.7% to 36.0% with BBFC, 22.4% to 27.9% with brinzolamide, and 20.6% to 31.3% with brimonidine.\nThe most common adverse drug reactions were ocular side effects, including hyperemia, blurred vision, allergic-type reactions, and discomfort.\nThe incidence of hyperemia of the eye was slightly lower with brinzolamide than with BBFC and brimonidine, whereas blurred vision and ocular discomfort were slightly more common with BBFC than with brinzolamide or brimonidine.", "label": []}
{"text": "The mean (SD) IOP before washout was 18.5 (4.0) mm Hg.\nThe mean increase in IOP after washout, using the mean of the 3 measurements, was 5.3 (4.2) mm Hg.\nThe percentage of eyes in which the increase in IOP using a single postwashout IOP differed from the increase in IOP using the mean of 3 measurements by more than 1.5 mm Hg was 35.1%, 25.6%, 34.2%, 30.0%, and 31.4% when the single measurement was made at 8 am, 12 pm, 4 pm, a randomly chosen single measure of those 3 times, and the time closest to that of the prewashout IOP, respectively.\nBy logistic regression, the 12 pm postwashout IOP had the lowest proportion of eyes differing from the mean (P < .001) and thus most closely approximated the mean diurnal IOP.", "label": []}
{"text": "Using an intent-to-treat analysis, we found that the median adherence rate in the 38 participants randomized to the intervention increased from 53% to 64% (P\u2009<\u2009.05).\nThere was no statistical change in 32 participants in the control group.\nTo assess the real efficacy of the intervention, the same comparison was performed for the participants who successfully completed the study after randomization.\nAnalyzed this way, the adherence rate in the 20 participants in the intervention group increased from 54% to 73% (P\u2009<\u2009.05), whereas there was again no statistical change in the 19 participants in the control group.\nEighty-four percent of the participants who received reminders agreed they were helpful and would continue using them outside the study.", "label": []}
{"text": "Seventy-seven patients were enrolled in the study, including 37 in the TA group and 40 in the control group.\nThere were no significant differences in success rates between the 2 groups (P=.60).\nIntraocular pressure and medication use were similar between the groups for each follow-up visit.\nDry eye scores were lower in the TA group at month 1 (P=.042), while flare scores were higher in the TA group on day 1 (P=.015) but lower at month 1 (P=.044).\nThe complication rates were higher in the TA group on day 1 (P=.04).\nAll other outcome measures were similar for both groups.", "label": []}
{"text": "The median logMAR visual acuity was not significantly different between the treated eyes in the 2 treatment groups (both, 0.90 [20/159]; P\u2009=\u2009.54).\nAbout 50% of treated eyes in both groups had visual acuity less than or equal to 20/200.\nSignificantly more patients in the IOL group had at least 1 adverse event after cataract surgery (contact lens, 56%; IOL, 81%; P\u2009=\u2009.02).\nThe most common adverse events in the IOL group were lens reproliferation into the visual axis, pupillary membranes, and corectopia.\nGlaucoma/glaucoma suspect occurred in 35% of treated eyes in the contact lens group vs 28% of eyes in the IOL group (P\u2009=\u2009.55).\nSince the initial cataract surgery, significantly more patients in the IOL group have had at least 1 additional intraocular surgery (contact lens, 21%; IOL, 72%; P\u2009<\u2009.001).", "label": []}
{"text": "The 50% glucose reached the vitreous in pseudophakic but not phakic individuals.\nGlucose significantly improved the mean contrast sensitivity at 12 cycles/degree compared with 0.9% saline by 0.26 log units (95% confidence interval [CI], 0.13-0.38; P\u2009<\u20090.001) and 0.40 log units (95% CI, 0.17-0.60; P\u2009<\u20090.001) in the follow-up study.\nThe intraocular pressure, refraction, and central corneal thickness were not affected by glucose; age was not a significant predictor of the response.", "label": []}
{"text": "During the CEE plus MPA intervention phase, the numbers of CHD cases were 196 for CEE plus MPA vs 159 for placebo (hazard ratio [HR], 1.18; 95% CI, 0.95-1.45) and 206 vs 155, respectively, for invasive breast cancer (HR, 1.24; 95% CI, 1.01-1.53).\nOther risks included increased stroke, pulmonary embolism, dementia (in women aged \u226565 years), gallbladder disease, and urinary incontinence; benefits included decreased hip fractures, diabetes, and vasomotor symptoms.\nMost risks and benefits dissipated postintervention, although some elevation in breast cancer risk persisted during cumulative follow-up (434 cases for CEE plus MPA vs 323 for placebo; HR, 1.28 [95% CI, 1.11-1.48]).\nThe risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02); cumulatively, there were 168 vs 216, respectively, cases of breast cancer diagnosed (HR, 0.79; 95% CI, 0.65-0.97).\nResults for other outcomes were similar to CEE plus MPA.\nNeither regimen affected all-cause mortality.\nFor CEE alone, younger women (aged 50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (nominal P\u2009<\u2009.05 for trend by age).\nAbsolute risks of adverse events (measured by the global index) per 10,000 women annually taking CEE plus MPA ranged from 12 excess cases for ages of 50-59 years to 38 for ages of 70-79 years; for women taking CEE alone, from 19 fewer cases for ages of 50-59 years to 51 excess cases for ages of 70-79 years.\nQuality-of-life outcomes had mixed results in both trials.", "label": []}
{"text": "For eyes without PDR at baseline, the 3-year cumulative probabilities for retinopathy worsening (P value comparison with sham with prompt laser) were 23% using sham with prompt laser, 18% with ranibizumab with prompt laser (P = .25), 7% with ranibizumab with deferred laser (P = .001), and 37% with triamcinolone with prompt laser (P = .10).\nFor eyes with PDR at baseline, the 3-year cumulative probabilities for retinopathy worsening were 40%, 21% (P = .05), 18% (P = .02), and 12% (P < .001), respectively.\nCONCLUSIONS AND RELEVANCE Intravitreal ranibizumab appears to be associated with a reduced risk of diabetic retinopathy worsening in eyes with or without PDR.\nIntravitreal triamcinolone also appears to be associated with a reduced risk of PDR worsening.\nThese findings suggest that use of these drugs to prevent worsening of diabetic retinopathy may be feasible.\nGiven the exploratory nature of these analyses, the risk of endophthalmitis following intravitreal injections, and the fact that intravitreal triamcinolone can cause cataract or glaucoma, use of these treatments to reduce the rates of worsening of retinopathy, with or without PDR, does not seem warranted at this time.", "label": []}
{"text": "A total of 660 patients were enrolled.\nBaseline mean IOP values were similar among treatment groups at all 4 time points.\nAt 3 months, the mean IOP of the brinzolamide-brimonidine group (16.3-19.8 mm Hg) was significantly lower than that of either the brinzolamide group (19.3-20.9 mm Hg; P \u2264 .002) or the brimonidine group (17.9-22.5 mm Hg; P < .001) across all time points.\nOne of 10 serious adverse events (chest pain, brinzolamide group) was judged as treatment related.\nA total of 129 patients experienced at least 1 treatment-related adverse effect (brinzolamide-brimonidine, 22.9%; brinzolamide, 18.6%; and brimonidine, 17.3%; P = .31), most of which were ocular.", "label": []}
{"text": "Twenty-six CACG eyes were randomized to receive phacoemulsification, and 24 eyes underwent trabeculectomy with mitomycin C. Phacoemulsification and trabeculectomy resulted in significant and comparable IOP reduction at 24 months after surgery (reduction of 8.4 mmHg or 34% for phacoemulsification vs. 8.9 mmHg or 36% for trabeculectomy; P=0.76).\nOver first 24 months, trabeculectomy-treated eyes required on average 1.1 fewer drugs than phacoemulsification-treated eyes (P<0.001).\nHowever, trabeculectomy was associated with significantly more surgical complications than phacoemulsification (46% vs. 4%; P=0.001).\nEight (33%) of 24 trabeculectomy eyes demonstrated cataract during follow-up.", "label": []}
{"text": "A total of 212 eyes of 212 patients were enrolled, including 107 in the tube group and 105 in the trabeculectomy group.\nAt 5 years, IOP (mean \u00b1 SD) was 14.4 \u00b1 6.9 mm Hg in the tube group and 12.6 \u00b1 5.9 mm Hg in the trabeculectomy group (P = .12).\nThe number of glaucoma medications (mean \u00b1 SD) was 1.4 \u00b1 1.3 in the tube group and 1.2 \u00b1 1.5 in the trabeculectomy group (P = .23).\nThe cumulative probability of failure during 5 years of follow-up was 29.8% in the tube group and 46.9% in the trabeculectomy group (P = .002; hazard ratio = 2.15; 95% confidence interval = 1.30 to 3.56).\nThe rate of reoperation for glaucoma was 9% in the tube group and 29% in the trabeculectomy group (P = .025).", "label": []}
{"text": "Early postoperative complications occurred in 22 patients (21%) in the tube group and 39 patients (37%) in the trabeculectomy group (P = .012).\nLate postoperative complications developed in 36 patients (34%) in the tube group and 38 patients (36%) in the trabeculectomy group during 5 years of follow-up (P = .81).\nThe rate of reoperation for complications was 22% in the tube group and 18% in the trabeculectomy group (P = .29).\nCataract extraction was performed in 13 phakic eyes (54%) in the tube group and 9 phakic eyes (43%) in the trabeculectomy group (P = .43).", "label": []}
{"text": "For both ET and CM eyes, there was a consistent increase in prevalence of astigmatism over time, increasing from 42% at 4 years to 52% by 6 years for the group of ET eyes and from 47% to 54%, respectively, in the CM eyes.\nThere was no statistically significant difference between the slopes (rate of change per month) of the ET and CM eyes for both astigmatism and high astigmatism (P = 0.75).", "label": []}
{"text": "The evaluable PK analysis set included data from 39 of 47 enrolled subjects.\nThe median peak plasma concentration value was higher in the <3-year age group (166 pg/ml) versus other groups (49, 16, and 26 pg/ml for the 3-<12-year, 12-<18-year, and \u226518-year age groups, respectively).\nThe median area under the concentration-time curve from zero to last measurable concentration value was also higher in the <3-year age group (2716 pg/min/ml) versus other groups (588, 106, and 380 pg/min/ml for the 3-<12-year, 12-<18-year, and \u226518-year age groups, respectively).\nLatanoprost acid was rapidly eliminated from the blood, with plasma concentrations undetectable within 10 to 30 minutes postdose in all but the <3-year age group.\nThere were no discontinuations or dose reductions due to adverse events or treatment-emergent adverse events.", "label": []}
{"text": "Insertion of the i-gel did not increase IOP.\nInsertion of an endotracheal tube increased IOP from 11.6 \u00b1 1.6 to 16.5 \u00b1 1.7 mmHg (P < 0.001).\nThe post-insertion IOP exceeded the pre-induction value (P < 0.05).\nInsertion of the LMA increased IOP from 13.0 \u00b1 1.5 to 14.7 \u00b1 1.8 mmHg (P < 0.01), but this did not exceed the pre-induction value.\nTracheal intubation significantly increased HR, SBP and DBP.\nInsertion of the LMA significantly increased HR and SBP.\nThese increases were significantly higher than those which followed insertion of the i-gel device.\nInsertion of the endotracheal tube or LMA resulted in a significant decrease in perfusion index which was maintained for 5 min following tracheal intubation and for 2 min after insertion of the LMA.\nInsertion of the i-gel device did not change perfusion index significantly.", "label": []}
{"text": "The cumulative 36-month incidences for CRVO and BRVO eyes, respectively, were 8.5% and 2.4% for NVI or NVG; 8.8% and 7.6% for NVD/NVE or PRH/VH.\nThere were no differences in incidences of neovascular events or risk of nonperfusion when comparing the 3 treatment groups within diseases.\nFor CRVO at 36 months, 16.6% of eyes with \u22655.5 disc areas of nonperfusion versus 4.0% of eyes with <5.5 disc areas of nonperfusion developed NVG (P = 0.0003); for BRVO at 36 months, 14.6% versus 2.4% developed NVD/NVE (P<0.0001).\nSimilar results were noted for most other neovascular events.\nNonperfusion was the only significant baseline factor for neovascularization in BRVO, with the risk of a neovascular event increasing with greater disc areas of nonperfusion, and the highest risk noted at \u22655.5 disc areas.", "label": []}
{"text": "Fifty-seven patients were randomized to undergo laser treatment and 59 were randomized to no laser (controls).\nAge, gender, spherical equivalent refraction, and intraocular pressure at baseline were similar between groups.\nOutcome data were available for 105 (90%) of recruited subjects, 52 in the laser treatment group and 53 in the no laser treatment group.\nPatients were followed up for a median of 35.9 months (range, 10-36 months) in the laser arm and 35.9 months (range, 1-36 months) in the control arm.\nEight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.\nThe proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.\nSurvival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.\nCataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).", "label": []}
{"text": "The study met the primary outcome, with 72% of treatment eyes versus 50% of control eyes achieving the criterion (P<0.001).\nAt 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.\nSixty-six percent of treatment eyes versus 48% of control eyes achieved \u226520% IOP reduction without medication (P = 0.003).\nThe overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.", "label": []}
{"text": "A total of 212 eyes of 212 patients were enrolled, including 107 in the tube group and 105 in the trabeculectomy group.\nAt 3 years, IOP (mean +/- standard deviation [SD]) was 13.0 +/- 4.9 mm Hg in the tube group and 13.3 +/- 6.8 mm Hg in the trabeculectomy group (P = .78).\nThe number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 1.0 +/- 1.5 in the trabeculectomy group (P = .30).\nThe cumulative probability of failure during the first 3 years of follow-up was 15.1% in the tube group and 30.7% in the trabeculectomy group (P = .010; hazards ratio, 2.2; 95% confidence interval, 1.2 to 4.1).\nPostoperative complications developed in 42 patients (39%) in the tube group and 63 patients (60%) in the trabeculectomy group (P = .004).\nSurgical complications were associated with reoperation and/or loss of > or =2 Snellen lines in 24 patients (22%) in the tube group and 28 patients (27%) in the trabeculectomy group (P = .58).", "label": []}
{"text": "The mean IOP at each hour at PGA-treated baseline was comparable among treatment groups.\nAfter initiation of adjunctive therapy, the mean IOP was lower and the mean change from baseline IOP was greater in the brimonidine group than in either the dorzolamide group or the brinzolamide group at 10 am and 4 pm at months 1 and 4 (P<0.001).\nAfter 4 months of adjunctive treatment, the mean IOP reduction from baseline at 10 am and 4 pm was 4.8 mmHg (21%) and 3.8 mmHg (19%) with brimonidine, 3.4 mmHg (16%) and 2.8 mmHg (14%) with dorzolamide, and 3.4 mmHg (16%) and 2.6 mmHg (13%) with brinzolamide (P<0.001 for brimonidine vs. dorzolamide and brinzolamide at each time point).\nEach of the study drugs was well tolerated, and all patients completed the study.", "label": []}
{"text": "The ophthalmic drug showed potential for the non-surgical treatment of age-related cataracts for participants after controlling for age, gender and daily activities and on a combined basis of repurchases behavior reports in more than 50,000 various cohort survivors, has been demonstrated to have a high efficacy and good tolerability for prevention and treatment of visual impairment determined for the older population with relative stable pattern of causes for blindness and visual impairment.\nThe mechanisms of prevention and reversal of cataracts with NAC ophthalmic drug are considered which include prevention by the intraocular released carnosine of free-radical-induced inactivation of proprietary lens antioxidant enzymes (superoxide dismutase); prevention of carbohydrate and metal-catalyzed autooxidation of ascorbic acid-induced cross-linking glycation reactions to the lens proteins; transglycation properties of carnosine, allowing it to compete for the glycating agent, protecting proteins (lens crystallins) against modification; universal antioxidant and scavenging activity towards lipid hydroperoxides, aldehydes and oxygen radicals; activation with l-carnosine ingredient of proteasome activity in the lens; chaperone-like disaggregating to lens crystallins activity of NAC and of its bioactivated principal carnosine.\nBlindness incidence increased with advancing age, such as cataract and glaucoma, which are by far the commonest causes of blindness in our sample and in all age groups, glaucomatous neurodegeneration can be treated with developed NAC autoinduction prodrug eye drops equipped with corneal absorption promoters.\nThe common blinding affections presenting in developed countries such as, senile macular degeneration, hereditary chorioretinal dystrophies, diabetic retinopathy are poorly represented in our current summary of vital-statistics and will be reported inherent in next N-acetylcarnosine ophthalmic drug studies.", "label": []}
{"text": "Twenty-seven CACG eyes were randomized into group 1, and 24 CACG eyes were randomized into group 2.\nCombined phacotrabeculectomy resulted in lower mean postoperative IOP than phacoemulsification alone at 3 months (14.0 vs. 17.0 mmHg, P = 0.01), 15 months (13.2 vs. 15.4 mmHg, P = 0.02), and 18 months (13.6 vs. 15.9 mmHg, P = 0.01).\nCombined phacotrabeculectomy resulted in 1.25 fewer topical glaucoma drugs (P<0.001) in the 24-month postoperative period, compared with phacoemulsification alone.\nCombined surgery was associated with more postoperative complications (P<0.001) and more progression of optic neuropathy (P = 0.03), compared with phacoemulsification alone.", "label": []}
{"text": "The prevalence of astigmatism in ET and CM eyes was similar at each test age.\nFor both groups, there was an increase in prevalence of astigmatism from approximately 32% at 6 months to approximately 42% by 3 years, mostly occurring between 6 and 9 months.\nAmong eyes that could be refracted, astigmatism was not influenced by zone of acute-phase ROP, presence of plus disease, or retinal residua of ROP.\nEyes with astigmatism and high astigmatism most often had WTR astigmatism.", "label": []}
{"text": "Thirty-five CACG eyes were randomized into group 1, and 37 CACG eyes were randomized into group 2.\nThere were no statistically significant differences (P>0.05) in mean IOP between the 2 treatment groups preoperatively and postoperatively, except at 1 month (P = 0.001) and 3 months (P = 0.008).\nCombined phacotrabeculectomy with adjunctive mitomycin C resulted in 0.80 less topical glaucoma drugs (P<0.001) in the 24-month postoperative period compared with phacoemulsification alone.\nThe differences in IOP control were, however, not associated with differences in glaucomatous progression.\nCombined surgery was associated with more postoperative (P<0.001) complications compared with phacoemulsification alone.", "label": []}
{"text": "Thirty-three patients were enrolled; 17 were assigned to nilvadipine and 16 were assigned to placebo; 13 in each group completed the study.\nNo significant intergroup difference was seen in age, refraction, or baseline values of any of the parameters.\nDuring the 3-year period, the IOP averaged 12.6 mmHg in the nilvadipine group and 12.8 mmHg in the placebo group (P>0.1), and no significant change from baseline or intergroup difference was seen in blood pressure or pulse rate.\nThe estimated slope of change in the MD was less negative in the nilvadipine than in the placebo group (-0.01 vs. -0.27 decibels/year; P = 0.040).\nThe NB(ONH) and NB(fovea) values remained increased compared with baseline for the study period by approximately 30% to 40% only in the nilvadipine group, and the intergroup difference was significant (P = 0.003 for NB(ONH) and P = 0.007 for NB(fovea)).", "label": []}
{"text": "After 12 months' follow-up, the mean (logMAR) distance visual acuity was 0.27 in the intervention group and 0.25 in the control group (p = 0.32).\nThe mean (logMAR) near visual acuities were -0.01 in the intervention group and -0.03 in the control group (p = 0.26).\nThe mean composite score on the National Eye Institute Visual Function Questionnaire was 84.3 in the intervention group and 86.4 in the control group (p = 0.49).", "label": []}
{"text": "Five hundred and twenty-seven (527) subjects comprised the safety population.\nA total of 290 of 356 bromfenac and 93 of 171 placebo subjects received 28 doses of test agent.\nNo clinically significant treatment-related systemic adverse effects or changes in liver chemistries were observed.", "label": []}
{"text": "Of the 388 patients evaluated in the trial, 81% (n = 274) had either POAG or CACG, combined into a single set (POAG/CACG) analyzed by intent-to-treat (ITT) criteria.\nSeparate ITT analyses were carried out for all participants (+PEXG/PG group), with similar results.\nThe treatment success rate was 60% in the CAT-152 group and 68% in the placebo group (P = 0.23).\nNo statistically significant differences emerged in the secondary end points.\nPatients requiring 5-FU for postsurgical management were more likely to be treatment failures (P = 0.0003).\nPatients with a primary diagnosis of PG (n = 49) had a higher success rate than those with other diagnoses (P = 0.0077).\nAdministration of CAT-152 was not associated with an increased incidence of adverse events.\nThe immunogenicity of CAT-152 was very low.", "label": []}
{"text": "Two hundred five subjects were enrolled; UBM images of 167 subjects were available for analysis.\nPlateau iris was found in 54 of 167 (32.3%) PACS eyes after LPI.\nQuadrantwise analysis showed that 44 of 167 (26.3%) eyes had plateau iris in 1 quadrant, 36 (21.5%) in 2 quadrants, 16 (9.5%) in 3 quadrants, and 2 (1.2%) in all 4 quadrants.\nPlateau iris was most commonly observed in the superior and inferior quadrants.", "label": []}
{"text": "Mean baseline IOP was 24.0+/-2.0 mmHg in the viscocanalostomy group and 23.7+/-2.6 mmHg in the trabeculectomy group (P = 0.7).\nMean postoperative IOP was 13.7+/-2.2 mmHg at 3 months, 14.8+/-3.3 mmHg at 6 months, and 14.9+/-3.0 mmHg at 12 months in the viscocanalostomy group and 12.1+/-4.0 mmHg at 3 months, 13.8+/-4.7 mmHg at 6 months, and 14.1+/-4.4 mmHg at 12 months in the trabeculectomy group.\nThere was no significant difference in the mean IOP between the groups at any time.\nAt 12 months, 17 patients (85%) in the viscocanalostomy group and 16 patients (80%) in the trabeculectomy group achieved an IOP of 20 mmHg or less without medication (P = 0.7).\nComplications included 2 cases (10%) of flat/shallow anterior chamber and 4 cases (20%) of hypotony in the trabeculectomy group, whereas intraoperative microperforation of Descemet's membrane occurred in 3 cases (15%) in the viscocanalostomy group.", "label": []}
{"text": "Fifty-seven percent of subjects fell at least once during follow-up.\nFalls occurred more frequently in the group randomized to receive the vision intervention (65% fell at least once; 758 falls in total) than in the control group (50% fell at least once; 516 falls in total).\nThe falls rate ratio using the negative binomial model was 1.57 (95% confidence interval (CI)=1.20-2.05, P=.001).\nFractures were also more frequent in the intervention group (31 fractures) than the control group (18 fractures; relative risk from proportional hazards model 1.74, 95% CI=0.97-3.11, P=.06).", "label": []}
{"text": "One hundred ninety patients were enrolled (mean age, 64.9+/-10.7 years).\nMean deviation and CPSD were not correlated with mean, peak, trough, or peak minus trough (P - T) IOP (Ps = 0.2-0.9).\nAmong patients with unilateral VF loss (n = 53 [27.9%]), there were no differences (Ps = 0.3-0.9) in any IOP parameter between the normal VF eye and fellow glaucomatous eyes.\nAmong patients with bilateral VF loss (n = 137 [72.1%]), mean, peak, trough, and P - T IOPs were similar in eyes with a better VF MD compared with eyes with a worse VF MD (Ps = 0.2-0.7).\nCross-classified contingency tables demonstrated no relationship (Ps = 0.1-0.3) between IOP and VF MD or CPSD using chi-square analysis.", "label": []}
{"text": "Mean CCT was 572.6+/-37.4 microm (range, 458.5-695.6 microm).\nThe CCT was higher in younger patients, male patients, and diabetic patients.\nMean CCTs for the 429 patients receiving dorzolamide were 574.2+/-38.48 microm (range, 458.5-695.6 microm) and 571.0+/-36.21 microm (469.7-690.1 microm) for the 425 patients receiving placebo (P = 0.205).\nCentral corneal thickness did not correlate with refraction, baseline IOP, or systemic hypertension.", "label": []}
{"text": "A total of 212 eyes of 212 patients were enrolled, including 107 in the tube group and 105 in the trabeculectomy group.\nAt one year, IOP (mean +/- SD) was 12.4 +/- 3.9 mm Hg in the tube group and 12.7 +/- 5.8 mm Hg in the trabeculectomy group (P = .73).\nThe number of glaucoma medications (mean +/- SD) was 1.3 +/- 1.3 in the tube group and 0.5 +/- 0.9 in the trabeculectomy group (P < .001).\nThe cumulative probability of failure during the first year of follow-up was 3.9% in the tube group and 13.5% in the trabeculectomy group (P = .017).", "label": []}
{"text": "In multivariate analyses, factors that predicted the development of OAG included older age (hazard ratio [HR], 1.32; 95% confidence interval [CI], 1.04-1.69), larger vertical cup-to-disc (C/D) ratio (HR, 1.34; 95% CI, 1.14-1.58), larger vertical C/D ratio asymmetry (HR, 1.46; 95% CI, 1.11-1.93), higher PSD (HR, 1.66; 95% CI, 1.15-2.38), and lesser central corneal thickness (HR, 1.32; 95% CI, 1.05-1.67).", "label": []}
{"text": "Intraoperative complications occurred in seven patients (7%) in the tube group and 10 patients (10%) in the trabeculectomy group (P = .59).\nPostoperative complications developed in 36 patients (34%) in the tube group and 60 patients (57%) in the trabeculectomy group during the first year of follow-up (P = .001).\nSurgical complications were associated with reoperation and/or loss of > or =2 lines of Snellen visual acuity in 18 patients (17%) in the tube group and 28 patients (27%) in the trabeculectomy group (P = .12).", "label": []}
{"text": "320 people were recruited.\nbeta radiation was given to 164; 20 (6%) were not seen again after surgery.\nOne year after surgery the estimated risk of surgical failure was 30% (95% confidence interval 22% to 38%) in the placebo arm compared with 5% (2% to 10%) in the radiation arm.\nThe radiation group experienced a higher incidence of operable cataract (18 participants) than the placebo group (five participants; P = 0.01).\nAt two years the estimated risks with placebo and beta radiation were, respectively, 2.8% (0.9% to 8.3%) and 16.7% (10.0% to 27.3%).", "label": []}
{"text": "Improvement of > or =5 letters' best-corrected VA was found in 19 of 34 (56%) eyes treated with intravitreal TA, compared with 9 of 35 (26%) eyes treated with the placebo (z(generalized estimating equation) = 2.73, P = 0.006).\nThe mean improvement in VA was 5.7 letters (95% confidence interval, 1.4-9.9) more in the intravitreal TA-treated eyes than in those treated with the placebo.\nAn increase of intraocular pressure (IOP) of > or =5 mmHg was observed in 23 of 34 (68%) treated versus 3 of 30 (10%) untreated eyes (P<0.0001).\nGlaucoma medication was required in 15 of 34 (44%) treated versus 1 of 30 (3%) untreated eyes (P = 0.0002).\nCataract surgery was performed in 15 of 28 (54%) treated versus 0 of 21 (0%) untreated eyes (P<0.0001).\nTwo eyes in the intravitreal TA-treated group required trabeculectomy.\nThere was one case of infectious endophthalmitis in the treatment group.", "label": []}
{"text": "The mean follow-up period was 20.4 (SD 12.4) months (PMMA) and 15.1 (SD 7.7) months (collagen) (P=NS).\nThe mean preoperative IOP was 21.4 (SD 7.1) mm Hg (PMMA) and 21.0 mm Hg (SD 5.4) (collagen).\nThe mean postoperative IOP was 7.4 (SD 4.5) mm Hg (PMMA) and 5.4 (SD 4.4) mm Hg (collagen) at day 1 (P=NS), 15.7 (SD 5.0) mm Hg (PMMA) and 14.7 (SD 5.0) mm Hg (collagen) at month 1 (P=NS), and 13.8 (SD 4.8) mm Hg (PMMA) and 13.3 (SD 2.4) mm Hg (collagen) at month 12 (P=NS).\nSeven patients had perforations of the trabeculo-Descemet membrane and were excluded from the analysis.\nAt the last follow-up visit, 42% of PMMA patients and 44% of collagen patients achieved an IOP of 21 mm Hg or less without medication (P=NS).\nThe number of medications was reduced from 2.4 (SD 1.0) to 0.6 (SD 0.6) (P<0.001) in the PMMA group, and from 2.4 (SD 1.1) to 0.7 (SD 0.8) (P<0.001) in the collagen group.\nThere were no significant differences between the 2 groups in postoperative and transient complications.", "label": []}
{"text": "Fifty-two patients completed the study (27 in the study group and 25 in the control group), with a mean follow-up of 12.3 months.\nComplete success rates were 77.8% for the study group and 84.0% for the control group 12 months after surgery (P>0.5); qualified success rates were 88.9% for the study group and 92.0% for the control group (P>0.6).\nMean IOP decreased from 26.0+/-10.0 mmHg to 11.6+/-4.1 mmHg in the study eyes (P<0.001) and from 24.9+/-9.7 mmHg to 13.0+/-4.1 mmHg in the control eyes (P<0.001).\nIntraocular pressure measurements in both groups were similar at all visits (P>0.05).\nThe study eyes had more diffuse blebs than the control eyes (62.5% > or =4 clock-hours vs. 22.7%; P = 0.012).\nPostoperative complications were similar in the study eyes (14.8%) and the control eyes (20.0%; P>0.6).", "label": []}
{"text": "A total of 212 patients were enrolled between October 1999 and April 2004.\nThe age of the study population was 71.0 +/- 10.4 years (mean +/- SD), and 53% were women.\nThe baseline IOP was 25.3 +/- 5.3 mm Hg (mean +/- SD).\nThere were no significant differences in the demographic and ocular characteristics between the 2 treatment groups.", "label": []}
{"text": "One hundred ninety patients were randomized between 1998 and 2000.\nMean age (+/-standard deviation) was 64.9+/-10.7 years.\nWomen comprised 59.5% of the patients.\nFifty-three patients (27.9%) had unilateral field loss.\nThe 137 patients with bilateral field loss were older than those with unilateral field loss: 65.7 versus 62.3 years of age (P<0.05).\nMean untreated diurnal intraocular pressures were similar between the eyes of the bilateral patients (mean, 15.5 mmHg in both eyes) and unilateral patients (mean, 16.0 mmHg in field loss vs. 15.6 mmHg in fellow eyes).\nVisual field mean deviation for all eyes was -5.4+/-4.7 decibels.\nCentral corneal thickness in 168 phakic patients was 543 +/- 35 microm (range, 435-655 microm); thickness was less than 500 microm in 15 eyes and was more than 600 microm in 11 eyes.\nMean vertical cup-to-disc ratio for all eyes was 0.67+/-0.15.\nUnilateral field loss patients had a larger cup-to-disc ratio in the field loss eye (0.75+/-0.12) than the fellow eye with a normal field (0.60+/-0.17, P<0.0001).\nDisc hemorrhage was present at baseline in 29 patients (32 eyes).", "label": []}
{"text": "During the course of the study, the mean percent reduction in IOP in the dorzolamide group was 15% after 6 months and 22% after 5 years.\nMean IOP declined by 9% after 6 months and by 19% after 5 years in the placebo group.\nAt 60 months, the cumulative probability of converting to an efficacy end point was 13.4% in the dorzolamide group and 14.1% in the placebo group (hazard ratio, 0.86; 95% confidence interval [CI], 0.58-1.26; P = 0.45).\nThe cumulative probability of developing an efficacy or a safety end point was 13.7% in the dorzolamide group and 16.4% in the placebo group (hazard ratio, 0.73; 95% CI, 0.51-1.06; P = 0.1).", "label": []}
{"text": "Overall, at 6 months 84% of patients had full retinal reattachment and 94% had stable posterior retinal reattachment.\nThere was no significant difference in success in the primary outcome measure (56%, treatment group; 51%, placebo group; P = 0.59) or in secondary outcome measures or rates of complications.\nSecondary macular pucker occurred less often in the treatment group (6% vs. 17% at 6 months, P = 0.068).", "label": []}
{"text": "Data were available for 76 eyes in 76 patients.\nTwenty-nine patients received no therapy; 24, oral acetazolamide; and 23, apraclonidine.\nOne fifth (6/29) of patients with glaucoma developed a pressure rise of > or =5 mmHg if untreated, and 3% (1/29) developed a pressure rise of >10 mmHg.\nIn comparison, no patients in the acetazolamide group developed a pressure rise of > or =5 mmHg (P = 0.02), and 1 of 24 in the apraclonidine group (P = 0.08) developed such a pressure rise, with none developing a pressure rise of >10 mmHg.\nWhen comparing all treated with nontreated, a reduction in the proportion with pressure rise was found (P = 0.01).\nAll of the patients who developed a pressure rise of > or =5 mmHg did so within the first hour.", "label": []}
{"text": "After a mean follow-up of 12.3 months, Kaplan-Meier survival analysis showed a probability of success of 59% at 18 months for the MMC group and 61% for the control group when the first criterion for success was used (IOP between 6 and 21 mmHg).\nWhen an IOP reduction of at least 30% was used as the criterion to define success, the Kaplan-Meier survival analysis demonstrated a probability of success at 18 months of 62% for the MMC group and 67% for the control group.\nThere were no significant differences in survival rates between the 2 groups with either criterion (P = 0.75 and P = 0.37, respectively).\nAfter 15 days postoperatively, the mean IOP did not significantly differ for both MMC and control eyes.\nMean numbers of postoperative antiglaucoma medications were similar in MMC-treated eyes and controls.\nThere was no significant difference between the incidences of postoperative complications in both groups.", "label": []}
{"text": "At 10 am (peak drug effect) on day 28, the mean IOP reduction from baseline was significantly greater with bimatoprost (9.3 mm Hg, 40.3%) than with timolol gel (7.1 mm Hg, 31.1%; P=.024, Wilcoxon rank sum test) or latanoprost (7.4 mm Hg, 33.3%).\nIn the overall analysis of IOP measured over the course of 24 hours, mean IOP was significantly lower with bimatoprost or latanoprost than with timolol gel (P<.001; analysis of repeated measures).\nThe analysis of repeated measures also showed a significant difference between bimatoprost and latanoprost (P=.003).\nIn the area-under-the-curve analysis, bimatoprost and latanoprost were superior to timolol gel (P< or =.018) but comparable to each other (P> or =.223).\nAll treatment regimens were well tolerated, with few discontinuations due to adverse events.\nThere were no significant effects on systemic safety parameters.", "label": []}
{"text": "Thirty-three patients completed the study.\nOn the last day of treatment, the mean diurnal intraocular pressure for latanoprost was 15.9 +/- 2.3 mmHg and for TDFC was 15.3 +/- 2.0 mmHg (P = 0.05).\nIndividual time points for intraocular pressure were not statistically different between groups except at the 10:00 PM time point, when the mean for TDFC was 14.6 +/- 2.7 mmHg and for latanoprost was 16.6 +/- 3.1 mmHg (P < 0.006).\nEighteen patients overall preferred latanoprost versus 2 patients for the fixed combination, generally because of the greater convenience of once daily dosing.\nAdverse events were not significantly different between groups except that a bitter taste was found more frequently with TDFC (n = 9) than with latanoprost (n = 0; P = 0.009).\nDespite screening to exclude intolerance to beta-blockers, a single patient had to discontinue the TDFC because of new-onset asthma.", "label": []}
{"text": "At the end of the 24-month follow-up, IOP of 21 mmHg or less and more than 6 mmHg was achieved in 76% in group 1 (n = 19) and in 80% in group 2 (n = 20; log-rank P = 0.60); an IOP between 6 and 16 mmHg was obtained in 56% in group 1 (n = 14) and in 72% in group 2 (n = 18; log-rank P = 0.17; Kaplan-Meier cumulative probability of success).\nComplications of viscocanalostomy included one intraoperative conversion into trabeculectomy; microruptures in Descemet's membrane in five eyes; three cases of iris incarceration in the Decemet's window, two of which caused early failure of the procedure requiring reoperation; and a 1-mm to 2-mm transient self-resolving hyphema in three cases.\nComplications of trabeculectomy included one case of postoperative bleb bleeding with early transient IOP spike; one early hyphema; five cases of postoperative hypotony, two of which had a positive Seidel test from the conjunctival suture; three cases of transient choroidal detachment, two of which had shallow anterior chamber.\nNo patient required reoperation.\nTwo eyes required argon laser suture lysis, and nine underwent one or more 5-FU injections, which caused punctate keratopathy in three eyes.", "label": []}
{"text": "The primary efficacy analysis was based on the modified intent-to-treat population.\nAt month 3, hour 2, the dorzolamide/timolol group had an adjusted mean (standard error) change in IOP of -5.04 (0.30) mmHg versus -5.41 (0.30) mmHg in the brimonidine + timolol group, with a treatment difference of 0.36 (0.40) mmHg (95% confidence interval [CI] of -0.42-1.14 mmHg).\nAt month 3, hour 0, the dorzolamide/timolol group had a change in IOP of -3.66 (0.29) mmHg versus -4.15 (0.28) mmHg in the brimonidine + timolol group, with a treatment difference of 0.49 (0.39) mmHg (95% CI of -0.27-1.25 mmHg).\nLikewise, at all other observed time points, the 95% confidence interval of the treatment difference was within +/- 1.5 mmHg.\nNinety-three patients (64%) in the dorzolamide/timolol group and 88 patients (60%) in the brimonidine + timolol group had adverse experiences that were deemed drug related by the investigator, for which 7 patients (5%) in the dorzolamide/timolol group and 8 patients (5%) in the brimonidine + timolol group were discontinued from the study.", "label": []}
{"text": "After GBE treatment, a significant improvement in visual fields indices was recorded: mean deviation (MD) at baseline versus MD after GBE treatment, 11.40 +/- 3.27 dB versus 8.78 +/- 2.56 dB (t = 8.86, P = 0.0001, chi-square test); corrected pattern standard deviation (CPSD) at baseline versus CPSD after GBE treatment, 10.93 +/- 2.12 dB versus 8.13 +/- 2.12 dB (t = 9.89, P = 0.0001, chi-square test).\nNo significant changes were found in intraocular pressure, blood pressure, or heart rate after placebo or GBE treatment.\nAny ocular and systemic side effects were recorded for the duration of the trial.", "label": []}
{"text": "Latanoprost and brimonidine reduced the average IOP by 3.6 +/- 1.9 mmHg (P < 0.001) and 2.5 +/- 1.3 mmHg (P < 0.001), respectively, with a significant difference between the two regimens (P = 0.009).\nBoth drugs significantly reduced IOP at each time point.\nLatanoprost decreased IOP significantly more than did brimonidine at 8 am (11.7 +/- 2.2 mmHg vs. 13.7 +/- 2.1 mmHg, P = 0.004) and 4 pm (11.4 +/- 2.1 mmHg vs. 13.2 +/- 2.9 mmHg, P = 0.004), but IOP was equal between the two agents at 12 noon (11.5 +/- 2.6 mmHg vs. 11.5 +/- 2.3 mmHg, P = 0.967).\nIOP was maintained at 12 mmHg or lower in 18 (66.7%) of 27 patients after treatment with latanoprost and in 9 (33.3%) of 27 patients after treatment with brimonidine.\nLatanoprost monotherapy reduced IOP by 30% in 8 patients (29.6%), but brimonidine monotherapy did not reduce IOP by that much in any of the patients.\nOPP increased after latanoprost treatment (P < 0.001) but did not increase after brimonidine treatment (P = 0.355).\nThere was no significant change in pulse rate or blood pressure.", "label": []}
{"text": "After a median follow-up period of 6 years (range, 51-102 months), retention was excellent, with only 6 patients lost to follow-up for reasons other than death.\nOn average, treatment reduced the IOP by 5.1 mm Hg or 25%, a reduction maintained throughout follow-up.\nProgression was less frequent in the treatment group (58/129; 45%) than in controls (78/126; 62%) (P =.007) and occurred significantly later in treated patients.\nTreatment effects were also evident when stratifying patients by median IOP, mean deviation, and age as well as exfoliation status.\nAlthough patients reported few systemic or ocular conditions, increases in clinical nuclear lens opacity gradings were associated with treatment (P =.002).", "label": []}
{"text": "One thousand seventy-seven subjects were randomized between January 1, 1997 and May 31, 1999.\nThe mean age was 57.03 +/- 10.3 years; 54.41% were women and 99.9% were Caucasian.\nMean IOP was 23.6 +/- 1.6 mmHg in both eyes.\nMean visual acuity was 0.97 +/- 0.11 in both eyes; mean refraction was 0.23 +/- 1.76 diopters in the right eye and 0.18 +/- 1.79 diopters in the left eye.\nPrevious use of medication for ocular hypertension was reported by 38.4% of the patients, systemic hypertension by 28.1%, cardiovascular diseases by 12.9%, and diabetes mellitus by 4.7%.\nThe qualifying VFs were normal and reliable according to protocol criteria.", "label": []}
{"text": "Thirty-three acute PACG eyes of 32 patients were randomized to receive immediate ALPI, whereas 40 acute PACG eyes of 32 patients had conventional systemic medical therapy.\nBoth treatment groups were matched for age, duration of attack, and IOP at presentation.\nThe ALPI-treated group had lower IOP levels than the medically treated group at 15 minutes, 30 minutes, and 1 hour after the start of treatment.\nThe differences were statistically significant.\nThe difference in IOP levels became statistically insignificant from 2 hours onward.\nThe duration of attack did not affect the efficacy of ALPI in reducing IOP in acute PACG.\nNo serious laser complications occurred, at least in the early postlaser period.", "label": []}
{"text": "Sufficient follow-up data were available from 24 of 25 patients in each of the two groups.\nThe follow-up ranged from 12 to 28 months and was evaluated at 12 months for all patients.\nThe mean IOP decreased from 27.3 to 15.5 mmHg in group 1 and from 29.0 to 17.5 mmHg in group 2.\nThe average number of medications decreased from 2.3 and 2.4 to 0.9 and 0.8 (P = 0.68; t test) in groups 1 and 2, respectively, at the 12-month visit.\nHypotony was more frequent in group 2, in which the only case of hypotony maculopathy occurred.\nThere was a tendency of more eyes with lower IOP values in this group.\nThe rate of loss of visual acuity of more than 2 lines was higher in group 2.\nFailures were more frequent in group 2 (7 of 24) compared with group 1 (1 of 24) (P = 0.04, chi-square test).", "label": []}
{"text": "Across both treatment groups, there was an overall decline in the percent of participants reporting symptoms over time.\nOf 43 possible symptoms, 12 symptoms were reported with greater frequency by the surgically treated group and 7 symptoms more frequently by the medically-treated group.\nThe surgical patients reported more total Symptom Impact Glaucoma (P = 0.005) and, in particular, more bother related to local eye symptoms.\nVery few treatment group differences were noted in visual functioning, although surgical patients reported more problems with activities related to their visual acuity (P = 0.024).\nThe percentage of patients across treatment groups reporting worry about blindness was 50% at baseline but declined to approximately 25% over time.", "label": []}
{"text": "Mean central corneal thickness was 573.0 +/- 39.0 microm.\nTwenty-four percent of the OHTS subjects had central corneal thickness > 600 microm.\nMean central corneal thickness for African American subjects (555.7 +/- 40.0 microm; n = 318) was 23 microm thinner than for white subjects (579.0 +/- 37.0 microm; P < 0.0001).\nOther factors associated with greater mean central corneal thickness were younger age, female gender, and diabetes.", "label": []}
{"text": "Before the laser treatment, 33 patients (50.0%) received brimonidine 0.2% and 33 patients (50.0%) received apraclonidine 0.5%.\nEight of 33 patients (24.2%) in the brimonidine-treated group and 9 of 33 patients (27.3%) in the apraclonidine group had postoperative IOP increases of 5 mmHg or more.\nThis was not statistically different (P = 0.80).\nBy the time of last follow-up examination, 3 of 33 patients (9.1%) in the brimonidine-treated group and 3 of 33 patients (9.1%) in the apraclonidine group had IOP increases of 10 mmHg or more.\nThis was also not statistically different (P > or = 0.95).\nThe mean IOP reduction from baseline in the brimonidine group (-2.8 +/- 2.8 mmHg) was not statistically different (P = 0.55) compared with the mean IOP reduction in the apraclonidine group (-3.6 +/- 3.3 mmHg).\nThere were no statistically significant changes in mean heart rate or blood pressure in either group except for a slight reduction in diastolic blood pressure at 1 hour (P = 0.005) in the brimonidine group (-5.2 +/- 7.4 mmHg) compared with the apraclonidine group (-0.2 +/- 6.4 mmHg).\nThere were no clinically significant side effects noted in either group.", "label": []}
{"text": "At month 3, the mean reduction in IOP from baseline at 8 AM was 9.16 mmHg (35.2%) with bimatoprost once daily, 7.78 mmHg (30.4%) with bimatoprost twice daily, and 6.74 mmHg (26.2%) with timolol twice daily.\nAt all follow-up visits, mean IOP reductions were significantly greater in the bimatoprost once daily group than in the timolol group at each time point (8 AM, 10 AM, and 4 PM; P < 0.001).\nTwice-daily dosing of bimatoprost also provided significantly greater mean reductions in IOP than timolol at most time points but was not as effective as once-daily dosing.\nBimatoprost was associated with significantly more hyperemia and eyelash growth than timolol, whereas timolol was associated with significantly more burning and stinging sensation in eyes.\nOverall, bimatoprost was well tolerated with few discontinuations because of adverse events.", "label": []}
{"text": "The correlations between QOL measures and clinical outcomes were in the expected direction, but relatively weak.\nAt initial diagnosis, difficulty with bright lights and with light and dark adaptation were the most frequently reported symptoms related to visual function, whereas visual distortion was the most bothersome.\nApproximately half of the patients reported at least some worry or concern about the possibility of blindness.\nWithin the Visual Activities Questionnaire, higher scores on the Peripheral Vision subscale were associated with more field loss (P < 0.01).\nIn regression analyses controlling for sociodemographics and nonocular comorbidities, increased visual field loss was significantly associated with higher dysfunction among five disease-specific QOL measures (P < 0.05).", "label": []}
{"text": "For both corneal endothelial cell density and corneal thickness, the mean percent changes from baseline were similar in all three treatment groups.\nMean percent endothelial cell change at 1 year from baseline for latanoprost, FC, and timolol was 0.3 +/- 2.2%, 0.1 +/- 1.8%, 0.0 +/- 2.5% (mean +/- standard deviation; 95% confidence interval: latanoprost vs timolol -0.2-1.0; FC vs timolol -0.4-0.7) and mean percent change in corneal thickness was -1.1 +/- 2.5%, -1.0 +/- 2.0%, 0.2 +/- 3.1%, respectively.", "label": []}
{"text": "From an overall baseline of 24.1 mmHg, latanoprost reduced IOP by 6.7 mmHg (28%) and unoprostone reduced IOP by 3.3 mmHg (14%).\nThe difference between the groups of 3.4 mmHg was significant (P: < 0.001, analysis of covariance; 95% confidence interval [CI]: -4.7 to -2.1) in favor of latanoprost.\nA >/=30% reduction in mean IOP from baseline was achieved by 44% of latanoprost-treated patients compared with 8% of unoprostone-treated patients.\nThe incidence of adverse events was low and comparable between the groups.", "label": []}
{"text": "At 3-year follow-up, the PCO rate and BCVA did not differ significantly between the two groups (P: > 0.05 for both).\nIn addition, there were no significant differences in IOP, number of medications, and filtration success rate between the two groups (P: > 0.05 for each).", "label": []}
{"text": "At 12 months, mean IOP reduction was 12.3 +/- 4.2 (sclerectomy) versus 14.1 +/- 6.4 mmHg (trabeculectomy) (P = 0.15), and an IOP </= 21 mmHg was achieved in 36 (92.3%) and 37 eyes (94.9%) (P = 0.9), respectively.\nComplications included three (7.7%) flat/shallow anterior chambers and one (2.6%) hypotony (trabeculectomy), whereas internal iris incarceration was encountered in two eyes (5.1%) (sclerectomy).", "label": []}
{"text": "At 1 year after combined surgery, mean (+/-SD) IOP and number of glaucoma medi- cation were 19.5+/-2.7 mmHg and 0.6+/-0.5 in the phaco-aspiration group, compared with 17.5+/-2.4 mmHg and 0.3+/-0.4 in the phaco-trab group.\nHyphema (38%) and ocular hypotony (14%) were observed in the phaco-trab group only, whereas blood reflux (52%) and descemetolyses (23%) were seen exclusively in the phaco-aspiration group.", "label": []}
{"text": "Thirty patients completed the study.\nTwo patients in the timolol group were withdrawn because of inadequate IOP control.\nCompared with baseline, the IOP after 2 weeks of treatment was statistically significantly reduced by 8.8 +/- 1.1 mmHg (mean +/- SEM, P < 0.001) in the latanoprost group, and by 5.7 +/- 0.9 mmHg (P < 0.001) in the timolol group.\nThe difference in IOP reduction between the two treatment groups was 3.1 +/- 1.5 mm Hg in favor of latanoprost (P = 0.04).\nThe main ocular adverse events reported in both treatment groups were conjunctival hyperemia and discomfort.", "label": []}
{"text": "There was a significant difference in IOP at 6, 9, and 12 months after surgery among the three groups (P = 0.021, 0.026, and 0.033, respectively ANOVA).\nAt 12 months, the mean IOP in group 3 was 9.8+/-3.7 mm Hg compared with 13.4+/-5.5 mm Hg in group 2.\n(P = 0.015) and 12.4+/-4.4 mm Hg in group 1 (P = 0.039).\nSuccess rate (21 mm Hg or less), number of antiglaucoma medications, and complications showed no statistical significant difference between the three groups at each postoperative visit.", "label": []}
{"text": "The combination was numerically superior at all study timepoints and was statistically superior at all timepoints except for month 2, hour 0 for timolol, and month 2, hour 2 for dorzolamide.\nThe safety profile of the combination reflected those of its two components.\nThe number of patients reporting ocular or local adverse experiences was greater for the combination (45%) and dorzolamide (45%) than for timolol (27%), with burning and/or stinging eye being the most frequently reported.", "label": []}
{"text": "Intraocular pressure reduction was greater on average in the combination group than in the dorzolamide and timolol groups.\nAt morning trough (month 3, hour 0), the mean reduction in IOP from baseline was 27.4% (-7.7 mmHg) for the combination, 15.5% (-4.6 mmHg) for dorzolamide, and 22.2% (-6.4 mmHg) for timolol.\nAt morning peak (month 3, hour 2), the mean IOP reduction from baseline was 32.7% (-9.0 mmHg), 19.8% (-5.4 mmHg), and 22.6% (-6.3 mmHg) for the combination, dorzolamide, and timolol, respectively.\nOverall, the incidence of clinical adverse experiences was comparable between the combination and each of its components.\nThe proportion of patients who discontinued from the study because of clinical adverse experiences was also comparable between the combination and dorzolamide, although it was significantly greater in the combination group than in the timolol group (7% vs. 1%, P = 0.035).\nSimilarly, comparable numbers of patients in the combination and dorzolamide groups reported ocular symptoms; however, when compared to the timolol group, more patients receiving the combination reported blurred vision, burning eye, stinging eye, and tearing eye.", "label": []}
{"text": "A total of 255 patients were randomized between 1993 and 1997 and will be followed for at least 4 years.\nAll had generally good health status; mean age was 68.1 years, and 66% were women.\nAt baseline, mean IOP was 20.6 mmHg and 80% of eyes had IOP less than 25 mmHg.", "label": []}
{"text": "Two years after surgery, success rates were 36%, 64%, and 78% in the IOL-alone, asp+IOL, and triple procedure groups, respectively (P<.001).\nHyphema (46%) and ocular hypotony (11%) were observed in the triple procedure group only, whereas blood reflux (61%) and descemetolysis (19%) were seen exclusively in the asp+IOL group.", "label": []}
{"text": "The mean of the maximum IOP change in the brimonidine 0.2% group was -2.6+/-3.6 mmHg, and the mean for the apraclonidine 1.0% group was -2.3+/-3.7 mmHg (P = 0.8).\nNo patient had a pressure spike greater than 10 mmHg.", "label": []}
{"text": "There were 44 OAG, 20 ACG, 6 mixed mechanism, and 4 congenital glaucoma patients.\nMean pretreatment IOP, mean short-term post-treatment IOP, and mean short-term IOP reduction (percentage) were 23.10 +/- 5.21 mmHg, 18.49 +/- 4.77 mmHg, and 4.6 mmHg (20%) for OAG; 22.80 +/- 5.70 mmHg, 18.65 +/- 5.75 mmHg, and 4.15 mmHg (18%) for ACG; 25.00 +/- 10.32 mmHg, 21.00 +/- 12.12 mmHg, and 4.0 mmHg (16%) for mixed mechanism; and 26.00 +/- 4.97 mmHg, 17.75 +/- 4.57 mmHg, and 8.25 mmHg (32%) for congenital glaucoma, respectively.\nMean long-term follow-up was 204 days for OAG and 213 days for ACG.\nOf the initially controlled OAG and ACG patients, at 3 months 96% and 100%, at 6 months 80% and 77%, and at 9 months 58% and 44%, respectively, were still controlled.\nSix patients discontinued brimonidine, three of these owing to allergy.", "label": []}
{"text": "All patients were followed up for 24 months.\nMore postoperative complications occurred in the MT group during the 2-year follow-up.\nOne month after surgery, IOP was 10 +/- 1.46 mmHg (range, 8-13) in the MT group and 12.12 +/- 1.63 mmHg (range, 8-14) in the AIGT group (Student's t test, P = 0.001).\nThree months after surgery, IOP was 11.5 +/- 1.59 mmHg (range, 8-14) and 12.75 +/- 1.57 mmHg (range, 10-16) in the MT and AIGT groups, respectively (Student's t test, P = 0.033).\nFrom the 6th to the 24th postoperative month, no statistically significant difference in IOP was found between the two groups.\nAt the end of follow-up, 14 of 16 eyes (87.5%) of the AIGT group and 13 of the 16 eyes (81.25%) of the MT group showed an IOP < or = 14 mmHg.", "label": []}
{"text": "The two groups were similar in age, race, and medical dependency.\nPost-ALT mean IOPs at 5 minutes, 1 hour, and 24 hours were significantly lower than pre-ALT mean IOPs in both apraclonidine (P < 0.001) and pilocarpine (P < 0.001) groups.\nIncidences of IOP spikes greater than 1, 3, and 5 mmHg at 1 hour post-ALT were 21.1%, 14.9%, and 8.8% for the apraclonidine group and 12.3%, 5.3%, and 4.4% for the pilocarpine group (P = 0.076, 0.015, and 0.18 chi-square test).\nIn the apraclonidine prophylaxis group, patients on long-term apraclonidine showed significantly higher incidence of post-ALT IOP spike than the patients without such long-term apraclonidine use (35.7%, 15 of 42 eyes, vs. 12.5%, 9 of 72 eyes; P = 0.003).\nIn addition, peri-ALT pilocarpine prophylaxis tended to be less effective in patients undergoing long-term pilocarpine therapy but without statistical significance (17.4%, 8 of 46 eyes, vs. 9.4%, 6 of 64 eyes; P = 0.17).", "label": []}
{"text": "Visual field decay showed greater correlation to IOP variation (range and peak) and mean IOP than IOP at start or degree of IOP reduction.\nThe relation between mean IOP and visual field decay in the whole group was not quite linear, with more decay at higher IOP levels.\nThe association between IOP regulation and visual field decay was most pronounced in capsular glaucoma, whereas the results in the small group of simple glaucomas were inconclusive.", "label": []}
{"text": "Randomized assignment resulted in a balanced distribution between treatment groups for most demographic and clinical measures assessed at enrollment.\nMore males than females were enrolled (55% were males), and a substantial percentage (38.1 %) of enrollees were blacks.\nMost enrollees (90.6%) were diagnosed with primary open-angle glaucoma; the remainder had either pseudoexfoliative (4.8%) or pigmentary (4.6%) forms of open-angle glaucoma.", "label": []}
{"text": "Compared with baseline measurements, both latanoprost and timolol caused a significant (P < 0.001) reduction of IOP at each hour of diurnal curve throughout the duration of therapy.\nReduction of IOP was 6.0 +/- 4.5 and 5.9 +/- 4.6 with latanoprost and 4.8 +/- 3.0 and 4.6 +/- 3.1 with timolol after 6 and 12 months, respectively.\nComparison of mean diurnal measurements with latanoprost and timolol showed a statistical significant (P < 0.001) difference at 3, 6, and 12 months.\nMean \"C\" was found to be significantly enhanced (+30%) only in the latanoprost-treated group compared with the baseline (P = 0.017).\nMean conjunctival hyperemia was graded at 0.3 in latanoprost-treated eyes and 0.2 in timolol-treated eyes.\nA remarkable change in iris color was observed in both eyes of 1 of the 18 patients treated with latanoprost and none of the 18 patients who received timolol.\nDarkening of the peripheral iris stroma was suspected in two patients treated with latanoprost.\nIn the timolol group, heart rate was significantly reduced from 72 +/- 9 at baseline to 67 +/- 10 beats per minute at 12 months.", "label": []}
{"text": "Clinical slit-lamp assessment of anterior chamber flare and cells showed no difference between Surodex-treated eyes and dexamethasone eyedrop-treated eyes.\nFlare meter readings showed lower flare levels in the Surodex group at all postoperative visits compared with the dexamethasone eyedrop group.\nFlare reduction in the Surodex group reached statistical significance at days 4, 8, 15, and 30 after surgery.\nAt 3 months, flare was reduced to preoperative levels in the Surodex group but was still raised in the dexamethasone eyedrop group.\nFive eyes in the dexamethasone eyedrop group required augmentation of steroids and were deemed therapeutic failures as opposed to one eye in the Surodex group.\nOne patient in the dexamethasone eyedrop group developed postoperative open-angle glaucoma with profound visual field loss and optic disc cupping, resulting in hand movements vision.\nNo significant difference in endothelial cell loss was noted between Surodex-inserted eyes and dexamethasone eyedrop-treated eyes for up to 1 year after surgery.", "label": []}
{"text": "Supervision had a positive effect on overall reliability (P = 0.04) but not on individual reliability parameters or any of the global VF indices.\nThere was no difference between Humphrey Field Analyzers I and II in the need for supervision.\nPredictors of need for supervision were low educational level and a prior test result with false-positive responses.\nPredictors of an unreliable test were advanced age and a prior test with a high proportion of fixation losses.", "label": []}
{"text": "The mean percentage reduction in intraocular pressure on day 1 in the group with releasable sutures was 55.2%, while only a 0.8% reduction in anterior chamber depth was noted.\nThis compared with figures of 59.3% and 10.1%, respectively, in the group without releasable sutures.\nHypotony (intraocular pressure < or =6 mm Hg) was noted in 8 (53%) of cases without releasable sutures and 3 (20%) of cases with releasable sutures.\nShallow anterior chamber (central anterior chamber depth, < or =1 mm) was noted in 5 (33%) of cases without releasable sutures and 1 (7%) of cases with releasable sutures.\nThe mean +/- SD final bleb score was 5.4 +/- 0.3 in the group with releasable sutures compared with 4.2 +/- 0.6 in the group without releasable sutures (P<.001).\nThe mean +/- SD final intraocular pressure at the end of 12 months was 16.9 +/- 1.2 mm Hg in the group without releasable sutures and 15.0 +/- 0.9 mm Hg in the group with releasable sutures (P<.001).\nFinal intraocular pressure was controlled (intraocular pressure < or =21 mm Hg) in all patients in the group with releasable sutures, giving a success rate of 100%, and in 12 patients in the group without releasable sutures, giving a success rate of 80%.", "label": []}
{"text": "Brimonidine and timolol produced significant (P < 0.001) and sustained mean reductions in IOP throughout the 1-year follow-up when measured at hour 0 (trough) and at hour 2 (peak).\nAt weeks 1 and 2 and month 12, significantly greater mean decreases in IOP measured at peak (P < or = 0.007) were observed in patients treated with brimonidine as compared to timolol, whereas the mean decreases in IOP measured at trough was significantly greater in patients treated with timolol as compared to brimonidine (P < 0.001) at all follow-up visits.\nBoth drugs were well-tolerated.\nThe incidence of adverse events was similar in both treatment groups, except for ocular allergy, oral dryness, and conjunctival follicles, which occurred more frequently in the brimonidine group, and burning-stinging, which occurred more frequently in the timolol group.\nPatients receiving timolol experienced significant decreases in heart rate at all follow-up visits.", "label": []}
{"text": "The combination was numerically superior at all study timepoints and was statistically superior at all timepoints except for month 2, hour 0 for timolol, and month 2, hour 2 for dorzolamide.\nThe safety profile of the combination reflected those of its two components.\nThe number of patients reporting ocular or local adverse experiences was greater for the combination (45%) and dorzolamide (45%) than for timolol (27%), with burning and/or stinging eye being the most frequently reported.", "label": []}
{"text": "Intraocular pressure reduction was greater on average in the combination group than in the dorzolamide and timolol groups.\nAt morning trough (month 3, hour 0), the mean reduction in IOP from baseline was 27.4% (-7.7 mmHg) for the combination, 15.5% (-4.6 mmHg) for dorzolamide, and 22.2% (-6.4 mmHg) for timolol.\nAt morning peak (month 3, hour 2), the mean IOP reduction from baseline was 32.7% (-9.0 mmHg), 19.8% (-5.4 mmHg), and 22.6% (-6.3 mmHg) for the combination, dorzolamide, and timolol, respectively.\nOverall, the incidence of clinical adverse experiences was comparable between the combination and each of its components.\nThe proportion of patients who discontinued from the study because of clinical adverse experiences was also comparable between the combination and dorzolamide, although it was significantly greater in the combination group than in the timolol group (7% vs. 1%, P = 0.035).\nSimilarly, comparable numbers of patients in the combination and dorzolamide groups reported ocular symptoms; however, when compared to the timolol group, more patients receiving the combination reported blurred vision, burning eye, stinging eye, and tearing eye.", "label": []}
{"text": "The control and MMC groups were similar in preoperative characteristics.\nHowever, the probability of PCO requiring YAG capsulotomy was significantly lower in the MMC group than in the control group (P = 0.004).\nAmong the MMC subgroups, MMC application for 3 minutes was most effective and significant when compared with that of the control group (P = 0.002).\nAlthough not as significant as the intraoperative use of MMC (P = 0.002), old age (P = 0.026) and presence of diabetes mellitus (P = 0.035) were also identified as significant beneficial factors for decreasing the incidence of YAG capsulotomy for PCO in Cox proportional hazard regression analysis.", "label": []}
{"text": "In both black and white patients throughout 7-year follow-up, the mean decrease in intraocular pressure was greater in eyes assigned to TAT, and the cumulative probability of failure of the first intervention was greater in eyes assigned to ATT.\nIn black patients, APDVF, APDVA, and APDV are less for the ATT sequence than for the TAT sequence throughout the 7 years.\nIn white patients, APDVF also favors the ATT sequence but only for the first year, after which it favors the TAT sequence through the seventh year; APDVA also favors the ATT sequence, but the ATT-TAT difference progressively diminishes over 7 years; and APDV favors ATT over TAT initially, but after 4 years, the advantage switches to and remains with TAT.", "label": []}
{"text": "Blacks in the study were younger than whites and had more systemic hypertension and diabetes than whites.\nThe visual field defects of blacks on average were substantially more severe than those of whites.\nIntraocular pressures and visual acuity scores were similar in the two groups.\nBlacks were more hyperopic and had relatively fewer disk rim hemorrhages than whites.", "label": []}
{"text": "Without adjunctive MMC, filtration success was significantly less in SGTP than in PGTP (P = 0.03).\nAdjunctive MMC significantly increased the success rate of SGTP (P = 0.02) but not that of PGTP (P = 0.89) over the average follow-up period of 2 years.", "label": []}
{"text": "In the first protocol, IOP (mmHg +/- standard deviation) was significantly (P = 0.02) lower in the dorzolamide (16.3 +/- 2.6) than in the contralateral control (19.9 +/- 2.9) eyes.\nAqueous humor formation (microliter/minute +/- standard deviation) also was lower (P = 0.02) in dorzolamide eyes (1.79 +/- 0.4 vs. 2.33 +/- 0.5).\nAfter oral acetazolamide 250 mg, IOP was unchanged in dorzolamide eyes (17.6 +/- 2.0 preacetazolamide vs. 17.9 +/- 2.0 postacetazolamide), whereas it was reduced (P = 0.003) in control eyes (20.5 +/- 2.2 preacetazolamide vs. 16.9 +/- 2.3 postacetazolamide).\nAqueous humor formation was reduced in control eyes (2.31 +/- 0.8 preacetazolamide vs. 1.73 +/- 0.6 postacetazolamide; P = 0.005) but not in dorzolamide-treated eyes (1.56 +/- 0.45 preacetazolamide vs. 1.77 +/- 0.39 postacetazolamide).\nIn the second protocol, acetazolamide 250 mg four times daily symmetrically reduced IOP and AHF in both eyes.\nAfter single-drop dorzolamide in one eye, IOP and AHF did not change significantly.\nAfter 4 to 7 days of acetazolamide and unilateral dorzolamide, IOP and AHF remained reduced to a similar level in dorzolamide and control eyes not receiving topical therapy.", "label": []}
{"text": "Latanoprost significantly reduced (P < 0.001) IOP by approximately 8 mmHg from pretreatment values, and this reduction was maintained over the 24-month treatment period with no sign of upward drift.\nLatanoprost is apparently free of any systemic side effect.\nThe most significant ocular side effect with latanoprost was an increase in iris pigmentation, which occurred in 51 patients.", "label": []}
{"text": "There were no significant differences in the mean number of postoperative glaucoma medications at 1, 2, 3, 4-6, and 9-12 months and at last follow-up (P > 0.05); mean change in corrected visual acuity best attained (P = 0.315) or at last follow-up (P = 0.223) between the silicone and acrylic groups.\nBoth groups had significant decreases in mean IOP and mean number of medications postoperatively at all times (P < 0.05).\nHowever, the postoperative IOP > 25 mmHg and IOP spike > 5 mmHg above preoperative IOP during the first month were significantly higher in the acrylic group (P = 0.026).\nThe mean postoperative IOP at 1 month in the acrylic group was also significantly higher than the silicone group (14.1 +/- 5.0, 11.2 +/- 3.9, P = 0.005).\nConversely, there were no significant differences in mean postoperative IOP at 2, 3, 4-6, and 9-12 months and at last follow-up between the silicone and acrylic groups (P > 0.05).\nSuture removal or release occurred significantly more frequently in the acrylic IOL group during the first month and the first 2 months (48.8% and 60.5%) than the silicone group (25.0% and 36.1%, P = 0.030 and 0.031, respectively).\nThere were no significant differences in postoperative complications or surgical interventions between the two groups (P > 0.05).", "label": []}
{"text": "The mean IOP of 19.5 mmHg during acetazolamide treatment was further reduced to 16.8 mmHg after topical administration of latanoprost, i.e., a decrease of 2.9 +/- 2.8 mmHg (15%, P < 0.001).\nAdministration of placebo to patients on acetazolamide resulted in an upward drift of 1.3 mmHg (6%, P = 0.03).\nA modest but statistically significant increase in conjunctival hyperemia was found in the latanoprost-treated group, but did not affect the masking.", "label": []}
{"text": "Fifty patients with a mean of 11.4 months' (range, 10-13 months) follow-up were analyzed.\nPatients with reduced preoperative facility of outflow (as defined by C < or = 0.28 microliter/min/mmHg) showed a significant improvement from a mean preoperative value of 0.24 +/- 0.04 microliter/min/mmHg to 0.41 +/- 0.22 microliter/min/mmHg at 1 year (P = 0.002, N = 19).\nAmong all patients, there was no significant change between mean preoperative C and last follow-up (0.39 +/- 0.23 vs. 0.46 +/- 0.38 microliter/min/mmHg, not significant [ns], N = 50).\nFurthermore, there was no significant change between mean preoperative and final IOP (23.7 +/- 4.1 vs. 23.3 +/- 3.9 mmHg, ns, N = 50).\nThere was a significant elevation of mean IOP on postoperative day 1 to 27 +/- 6.2 mmHg (P = 0.001, N = 50).\nPatients with IOP elevations greater than 8 mmHg on postoperative day 1 had significantly elevated IOP at 1 year compared to preoperative values (P = 0.02, N = 12).\nThere were no significant differences detected regarding C or IOP between single- or two-quadrant peritomy groups.", "label": []}
{"text": "After a mean follow-up of 9.6 months, medical treatment alone was successful in ten patients (90.9%), whereas needling alone was successful in one patient (7.1%) (P = 0.00003).\nIn the needling group, 92.9% of the eyes required aqueous humor suppressants, and 57.1% were considered qualified successes at the last follow-up (mean = 10.1 months).\nAt the last follow-up examination, there was no statistically significant difference between the mean number of medications in both groups (P = 0.797).\nFurther glaucoma surgery was performed in five patients (35.7%) undergoing needling and one patient (9.1%) receiving medical treatment (P = 0.162).", "label": []}
{"text": "Ocular pressure decreased 2 minutes after propofol infusion (p < 0.0001) and remained significantly lower than in the control group throughout the study period.\nAll patients remained awake and cooperative during all procedures.\nMean BP and HR were kept constant throughout the study.", "label": []}
{"text": "In group 1 of cohort 1, compared with oil-treated eyes, gas-treated eyes had a higher rate of complete retinal reattachment from 18 to 36 months (P < .05).\nNo other differences were found.\nIn group 2 of cohort 1, no notable differences were found between treatment arms.\nIn cohort 2, during 6 years of follow-up, attachment of the macula was maintained for all eyes.\nNo notable differences in the rates of complete retinal attachment, visual acuity of 5/200 or better, or glaucoma were found between treatment groups.\nIn contrast, gas-treated eyes had more hypotony (P < .001).\nSilicone oil-treated eyes that underwent subsequent surgery were more likely to have the oil retained (P = .02).\nCompared with oil-retained eyes, oil-removed eyes had higher rates of complete posterior attachment (P = .01) and of a visual acuity of 5/200 or better (P < .001) and less keratopathy (P < .05).\nCompared with oil-removed eyes, gas-treated eyes had a worse visual acuity outcome (P < .05) and more hypotony (P < .01).", "label": []}
{"text": "At 1 year, the mean percent reduction in intraocular pressure at peak of 2% dorzolamide, 0.5% timolol, and 0.5% betaxolol was approximately 23%, 25%, and 21%, respectively.\nAt afternoon trough, the mean percent reduction in intraocular pressure was 17%, 20%, and 15% for dorzolamide, timolol, and betaxolol, respectively.", "label": []}
{"text": "Sixty one percent of patients treated with apraclonidine maintained adequate IOP control throughout the study, avoiding additional surgery compared to 33.9% patients treated with placebo (P < .001).\nApraclonidine treatment resulted in significantly more patients achieving either an additional > or = 20% reduction in IOP from baseline (resulting in an IOP < or = 20 mm Hg) (P < 0.05).\nThe most common ocular complications were conjunctival hyperemia (12.6%), itching and foreign body sensation (6.8%), and tearing (4.5%).\nThe most frequent non-ocular adverse events related to apraclonidine were dry mouth (4.5%) and unusual taste perception (2.2%).", "label": []}
{"text": "Mean age for the 725 patients is 65 years, with 43% of patients in the study age 70 or older.\nDespite the older age of this population, more than half (53%) of the patients are male.\nOne hundred and eighty-one patients were randomized into the nonperfused group and 155 into the macular edema group.\nFollow-up in the CVOS will be completed in February 1994 when most patients are expected to have completed the planned 3 years.", "label": []}
{"text": "Mean IOP at morning trough (8 AM) decreased from 27.1 mm Hg at baseline to 23.5 mm Hg on day 29 with dorzolamide (-13.3%) compared with a decrease from 27.1 mm Hg to 26.4 mm Hg with placebo (-2.3%).\nPeak activity occurred 2 hours after administration, with IOP decreasing from 26.8 mm Hg at baseline to 21.8 mm Hg on day 29 with dorzolamide (-18.4%) vs 26.1 mm Hg to 25.5 (-2.4%) with placebo.\nMean corneal thickness was slightly increased for the dorzolamide-treated group compared with the placebo-treated group (0.009 mm vs 0.001 mm, respectively, P < .05) and changes in endothelial cell counts were similar (-24 cells/mm2 vs -27 cells/mm2, respectively, P > .25).\nMean carbonic anhydrase isoenzyme II activity in red blood cells decreased to 21% of baseline in dorzolamide-treated patients.\nThere were no clinically significant differences in ocular or laboratory parameters between the dorzolamide and placebo groups.", "label": []}
